Baker Bros. Advisors LP Madrigal Pharmaceuticals, Inc. Transaction History
Baker Bros. Advisors LP
- $8.39 Billion
- Q1 2025
A detailed history of Baker Bros. Advisors LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 1,974,590 shares of MDGL stock, worth $669 Million. This represents 7.8% of its overall portfolio holdings.
Number of Shares
1,974,590
Previous 1,974,590
-0.0%
Holding current value
$669 Million
Previous $609 Million
7.34%
% of portfolio
7.8%
Previous 6.75%
Shares
8 transactions
Others Institutions Holding MDGL
# of Institutions
368Shares Held
23.2MCall Options Held
979KPut Options Held
432K-
Janus Henderson Group PLC London, X02.21MShares$748 Million0.42% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.1MShares$712 Million39.89% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.02MShares$685 Million10.84% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$676 Million10.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$573 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.8B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...